Blood volume and albumin transudation in critically ill COVID-19 patients

Jan Bakker1,2,3,4*, James M. Horowitz5, Jackie Hagedorn1, Sam Kozloff1, David Kaufman1 and Ricardo Castro4

To the Editor.

The SARS-CoV-2 infection (COVID-19) in critically ill patients presents as a viral pneumonia and inflammation affecting the endothelium [1] with unclear consequences for fluid leakage to the extravascular space. Nevertheless, the adapted Surviving Sepsis Guidelines advocate a conservative fluid strategy [2]. By using a radiolabeled albumin tracer, the total blood volume (TBV), red blood cell volume (RBCV), plasma volume (PV), and the albumin transudation rate (ATR) can be measured [3]. In six mechanically ventilated patients (admitted March/April 2020), the TBV was measured [4] as advanced hemodynamic monitoring was not used, and the volume status was unclear. The volumes measured were corrected for the ideal body weight of a corresponding healthy individual, and deviations were calculated. The results of only the TBV, RBCV, and PV were communicated with the treatment team.

We retrospectively analyzed these data together with the ATR. Albumin transudation rate is presented as a numeric value with 0.0025 (0.25%/min exiting the circulation) serving as the normal reference threshold. We report absolute variation (values at admission minus value at day of measurement for each case), and day-indexed values, calculated by dividing the absolute variation by the number of days in the ICU. We performed univariate regression between albumin transudation and variables of interest. In the multivariate regression, we tested variables that showed statistical significance in the univariate analysis and other that did not reach the significance threshold but had clinical relevance. Data are expressed as mean ±1 standard deviation unless otherwise indicated. A p value of equal or less than 0.05 was considered significant. None of the patients was diagnosed with a secondary infection the days before the measurement. Age of the patients was 66 ±1 year with a mean weight of 86.3 ±15.7 kg. Only one patient did not have any comorbidity on admission where the most frequent comorbidity was diabetes (four patients, two in combination with hypertension). Four patients died, all of whom developed complete renal failure. At the time of measurement, all patients had stable hemodynamics only one patient received vasopressor support (norepinephrine 0.42 mcg/kg/min). Results are shown in Table 1. Three of the four clinically hypervolemic patients (assessed by fluid balance and extend of peripheral edema), TBV showed a decreased value from ideal body weight. The median ATR was 0.46%/min (range 0.12–0.82). There was a strong linear relationship between the day of admission and ATR ($R^2=0.99$, $p<0.0001$) and a curve linear relationship with the deviation of the TBV ($R^2=0.63$, $p<0.03$) (Fig. 1).

In an exploratory multivariate regression model, we found TBV deviation ($p=0.022$) and net fluid balance since admission ($p=0.018$) and CRP at day of measurement ($p=0.043$) to explain 99% of the variation in ATR.

Although endothelial damage is believed to be an important part of COVID-19 and related to the severity of illness [5] and aggregates of red and white blood cells in the microcirculation have been reported [6], extensive capillary leakage has not been reported before. As a nosocomial bacterial infection had not been confirmed in any of the patients, the severity of COVID-19 and the...
Table 1 Characteristics of individual patients at day of blood volume measurement

| Parameter at time of measurement | Pat 1 #S | Pat 2 %NS | Pat 3 NS | Pat 4 NS | Pat 5 #NS | Pat 6 S | Mean ± SD Median IQR |
|----------------------------------|---------|-----------|----------|----------|-----------|---------|---------------------|
| ICU Admission                    | March 2020 | March 2020 | April 2020 | April 2020 | April 2020 | April 2020 | 66 ± 11 (68–73)     |
| Day of ICU admission at measurement | 14 | 20 | 11 | 13 | 7 | 2 |                      |
| Age (years) | Male/female | 70|M | 69|M | 49|M | 62|M | 66|F | 81|M |                      |
| Height (cm) | 1.75 | 1.73 | 1.65 | 1.73 | 1.58 | 1.52 | 166 ± 0.09 | 1.69 (1.57–1.74) |
| Weight (kg) | 76.2 | 78.0 | 77.8 | 67.8 | 93.9 | 61.8 | 75.9 ± 10.9 | 77.0 (66.3–82.0) |
| Ideal body weight (kg) | 70.0 | 69.0 | 61.0 | 69.0 | 51 | 50.0 | 61.7 ± 9.2 | 65.0 (50.8–69.3) |
| Heart rate (b/min) | 95 | 104 | 97 | 69 | 112 | 72 | 92 ± 17 | 96 (71–106) |
| Systolic arterial pressure (mmHg) | 137 | 72 | 97 | 94 | 146 | 96 | 107 ± 28 | 97 (89–138) |
| Diastolic arterial pressure (mmHg) | 56 | 38 | 66 | 48 | 52 | 42 | 50 ± 10 | 50 (41–59) |
| Mean arterial pressure (mm Hg) | 79 | 50 | 76 | 66 | 75 | 58 | 67 ± 11 | 71 (56–77) |
| Lactate (mmol/L) | 1.5 | 1.6 | 1.3 | 2.5 | 1.8 | 1.4 | 1.7 ± 0.4 | 1.6 (1.4–2.0) |
| C reactive protein at measurement (mg/L) | 3 | 239 | 409 | 282 | 263 | 50 | 208 ± 153 | 251 (38–313) |
| Inspired oxygen fraction | 0.4 | 0.8 | 0.7 | 1 | 0.8 | 0.4 | 0.68 ± 0.24 | 0.75 (0.4–0.9) |
| Pulse oximetry (%) | 97 | 95 | 96 | 95 | 91 | 96 | 95 ± 2 | 96 (94–97) |
| Net fluid balance day before measurement (L) | −0.9 | 1.2 | 1.3 | −0.3 | −0.9 | 3 | 0.6 ± 1.5 | 0.45 (−0.9 to 1.7) |
| Fluids IN day before measurement (L) | 3.6 | 2.1 | 2.6 | 1.7 | 3.1 | 3.2 | 2.7 ± 0.7 | 2.9 (2.0–3.3) |
| Urine output day before measurement (L) | 4.5 | 0.7 | 0.8 | 2.7 | 1.8 | 0.7 | 1.9 ± 1.5 | 1.3 (0.7–3.2) |
| Fluids in since admission (L) | 36.8 | 41 | 17.2 | 19.8 | 15.4 | 3.8 | 22.3 ± 14.0 | 18.5 (12.5–37.9) |
| Net fluid balance since admission (L) | 8.2 | 10 | 5.9 | 3.0 | 0.3 | 4.0 | 5.2 ± 3.5 | 5.0 (2.3–8.7) |
| Clinical assessment of volume status | Hyper | Hyper | Eu | Hyper | Hyper | Hypo | Hyper | Hypo |                      |
| Total blood volume (mL) | 4200 | 4290 | 5360 | 3990 | 4870 | 4552 | 4544 ± 502 | 4421 (4223–4791) |
| Red cell volume (mL) | 1215 | 935 | 1391 | 841 | 1220 | 1370 | 1162 ± 227 | 1218 (1005–1333) |
| Plasma volume (mL) | 2985 | 3355 | 3969 | 3149 | 3650 | 3182 | 3382 ± 366 | 3269 (3157–3576) |
| Total blood volume dev (%) | −16.6 | −17.3 | −15.2 | −18.9 | +3.3 | +17.2 | −7.9 ± 14.8 | −15.9 (−17.7 to 6.8) |
| Red cell volume dev (%) | −41% | −56% | −26% | −58% | −28% | −13% | −34 (−56 to −23) |
| Plasma volume dev (%) | −0% | 9% | 44% | 8% | 21% | 38% | 15% (6–39) |
| Albumin transudation rate (%/min) | 0.58 | 0.82 | 0.43 | 0.49 | 0.24 | 0.12 | 0.45 ± 0.25 | 0.46 (0.21–0.64) |

Mean ± SD and median (IQR 25, 75)

% = being treated with norepinephrine, # = being treated with diuretic, S = survivor, NS = non-survivor

Hyper: hypervolemia, Eu: euvolemia, Hypo: hypovolemia. Total blood volume deviation: absolute and relative deviation of the expected total blood volume of a healthy individual.
systemic inflammatory response could be a more likely explanation. This vascular leakage could result in tissue edema and ultimately organ dysfunction as seen in these patients. Although this may suggest a role for the use of specific fluids (such as colloids) in this disease, our current data do not allow such recommendation. Given the only one-time measurement results should be interpreted with caution. This study could be seen as a unique exploratory study in COVID-19 patients. We have therefore initiated a multicenter prospective study to improve our understanding of blood volume and vascular leakage in critically ill COVID-19 patients (NCT04517695).

Acknowledgements
Not applicable.

Authors’ contributions
JB contributed to acquisition of data, the writing of the manuscript, analysis of the data, and construction of the figure and table. JMH, JH, and DK contributed to the writing of the manuscript. SK contributed to acquisition of data and the writing of the manuscript. RC contributed to the writing of the manuscript, analysis of the data, and the construction of the figure and table. All authors read and approved the final manuscript.

Funding
The study was not supported. The prospective study that has started is supported by the Daxor Company that performs the analysis of the samples for participating centers.

Availability of data and materials
Supporting data are available upon request to the corresponding author 3 months after publication.

Fig. 1 Relationship between the albumin transudation rate (ATR) and the deviation of the total blood volume from ideal (TBV deviation)

Declarations

Ethics approval and consent to participate
As the measurements of blood volume were done on clinical indication and the retrospective analysis of the data did not contain patient-specific information, the IRB decided that this study did not require additional informed consent. The communication with the IRB on this topic is included as a supplement.

Consent for publication
Not applicable.

Competing interests
JB has received consulting grants from Daxor Company. Other authors have no competing interest to declare.

Author details
1 Division of Pulmonary, Critical Care, and Sleep Medicine, New York University School of Medicine, New York, NY, USA. 2 Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA. 3 Department of Intensive Care Adults, Erasmus MC University Medical Center, Rotterdam, Netherlands. 4 Department of Intensive Care, Pontificia Universidad Católica de Chile, Santiago, Chile. 5 Division of Cardiology, New York University School of Medicine, New York, NY, USA.

Received: 30 March 2021 Accepted: 21 July 2021
Published online: 31 July 2021

References
1. Pons S, Fodil S, Azoulay E, Zafrani L. The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection. Crit Care. 2020;24(1):353.

2. Alhazzani W, Moller MH, Arabi YM, Loeb M, Gong MN, Fan E, Oczkowski S, Levy MM, Derde L, Dzierba A, et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Crit Care Med. 2020;48(8):e440–69.
3. Feldschuh J, Enson Y. Prediction of the normal blood volume. Relation of blood volume to body habitus. Circulation. 1977;56(4 Pt 1):605–12.
4. Manzone TA, Dam HQ, Soltis D, Sagar VV. Blood volume analysis: a new technique and new clinical interest reinvigorate a classic study. J Nucl Med Technol. 2007;35(2):55–63 (quiz 77, 79).
5. Fraser DD, Patterson EK, Slessarev M, Gill SE, Martin C, Daley M, Miller MR, Patel MA, Dos Santos CC, Bosma KJ, et al. Endothelial injury and glycocalyx degradation in critically ill coronavirus disease 2019 patients: implications for microvascular platelet aggregation. Crit Care Explor. 2020;2(9):e0194.
6. Favaron E, Ince C, Hilfy MP, Ergin B, van der Zee P, Uz Z, Wendel Garcia PD, Hofmaenner DA, Acevedo CT, van Boven WJ et al. Capillary leukocytes, microaggregates, and the response to hypoxemia in the microcirculation of coronavirus disease 2019 patients. Crit Care Med 2021;49:661–70.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.